Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 559-571

  Falzoi, Matteo ^a   Mossa, Alessandra ^b   Congeddu, Elena ^b   Saba, Luisella ^b   Pani, Luca ^a,b,c  

^a CNR   (Italy)

^b Parco Scientifico e Tecnologico della Sardegna   (Italy)

^c Parco Scientifico e Tecnologico della Sardegna   (Italy)

Author keywords

CYP2C19; CYP2C9; CYP3A4; CYP3A5; CYP450; Drug treatment; Individualized therapy; Mass spectrometry; Pharmacogenetics

Indexed keywords

ALKALINE PHOSPHATASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ARTICLE; CAUCASIAN; DNA POLYMORPHISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OUTCOME ASSESSMENT; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CYTOCHROME P-450 CYP3A; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC TESTING; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77950366386     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.172     Document Type: Article

References (16)

1. Shastry BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 6(1), 16-21 (2006).
2. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
3. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007).
4. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4), 193-200 (2004).
5. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug. Deliv. Rev. 54, 1271-1294 (2002).
6. van Schaik RH: CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist. Updat. 11(3), 77-98 (2008).
7. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52(4), 349-355 (2001).
8. Kirchheiner J, Seeringer A: Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta. 1770(3), 489-494 (2007).
9. Veenstra DL, Blough DK, Higashi MK et al.: CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77(5), 353-364 (2005).
10. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006).
11. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005).
12. Ragoussis J: Genotyping technologies for all. Drug Discov. Today Technologies. 3(2), 115-122 (2006).
13. Ragoussis J, Elvidge GP, Kaur K, Colella S: Matrix-assisted laser desorption/ionisation, time-of-fight mass spectrometry in genomics research. PLoS Genet. 2(7), E100 (2006).
14. Tost J, Gut IG: Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin. Biochem. 38, 335-350 (2005).
15. van den Boom D, Ehrich M: Discovery and identifcation of sequence polymorphisms and mutations with MALDI-TOF MS. Methods Mol. Biol. 366, 287-306 (2007).
16. McGuigan FE, Ralston SH: Single nucleotide polymorphism detection: allelic discrimination using TaqMan. Psychiatr. Genet. 12(3), 133-136 (2002).